pd 153035 has been researched along with Glioblastoma in 1 studies
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glioblastoma (GB) is the most frequent primary brain tumor in adults with a dismal prognosis despite aggressive treatment including surgical resection, radiotherapy and chemotherapy with the alkylating agent temozolomide." | 2.87 | Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. ( Harter, PN; Mittelbronn, M; Pietsch, T; Reuter, D; Ronellenfitsch, MW; Senft, C; Steinbach, JP; Urban, H; Westphal, M; Zeiner, PS, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ronellenfitsch, MW | 1 |
| Zeiner, PS | 1 |
| Mittelbronn, M | 1 |
| Urban, H | 1 |
| Pietsch, T | 1 |
| Reuter, D | 1 |
| Senft, C | 1 |
| Steinbach, JP | 1 |
| Westphal, M | 1 |
| Harter, PN | 1 |
1 trial available for pd 153035 and Glioblastoma
| Article | Year |
|---|---|
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal, Humanized; Basic Helix-Loop-Helix Tran | 2018 |